Clinical Trial

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-15; most recent amendment 2026-02-05.
Status change: Not Yet Recruiting → Recruiting 2021-12-19
Trial Details
NCT Number NCT04930432
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Enrollment 400 participants
Start Date 2021-09-24
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-10